Featured guest speaker Dr. Stephen Harrison, Medical Director for Pinnacle Clinical Research, discusses how pairing FibroScan VCTE & CAP scores with AST blood markers can cost-effectively identify patients with a high probability of fibrotic-NASH (NAS>4, F≥2). Dr. Harrison will describe the recently published data which represents the first non-invasive diagnostic platform for the identification of patients for clinical trial consideration and potentially fatty liver pharmaceutical treatment.
Impact of combining direct biomarkers of VCTE™ and CAP™ with AST
The FAST™ score calculator is a tool for clinicians to calculate the probability of a patient with a suspicion of NAFLD as having active fibrotic-NASH (NASH+NAS ≥4+ F≥2). The calculator takes into account LSM by VCTE™, CAP™, and AST, and was developed based on a prospective multicenter study and published in peer-reviewed literature. The FAST™ score and calculator are presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and healthcare issues, it is not a substitute for or replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions._1593715513622